ZYNLONTA: payments to doctors
Payments that named ZYNLONTA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $757K
- Providers
- 2,598
- Transactions
- 4,058
- Average per transaction
- $187
The per-transaction average — $187 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,598 providers the average total is $291, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| ADC Therapeutics America, Inc. | $728,320 | 96.2% |
| Swedish Orphan Biovitrum AB | $28,955 | 3.8% |